|
1）Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist. 2007; 12: 664-89
|
|
|
|
2）Mahindra A, Laubach J, Raje N, et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2912; 9: 135-43
|
|
|
|
|
|
3）The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathy, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749-57
|
|
|
|
|
|
4）Greipp P, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005; 23: 3412-20
|
|
|
|
|
|
5）Kumar SK, Rajkumar V, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-20
|
|
|
|
|
|
6）NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1. 2011 (www. nccn. org)
|
|
|
|
|
|
7）Dispenzieri A, Lacy MQ, Greipp PR. Multiple myeloma. In: Greer JP, et al. editors. Wintrobe’s Clinical Hematology Volume 2. Philadelphia: Lippincott Williams & Wolters Kluwer; 2009. p. 2372-438
|
|
|
|
|
|
8）Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999; 13: 79-90
|
|
|
|
|
|
9）Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008; 38: 32-46
|
|
|
|
|
|
10）Stevens LA, Coresh J, Sehmind CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51: 395-406
|
|
|
|
|
|
11）Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010; 28: 4976-84
|
|
|
|
|
|
12）Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-100
|
|
|
|
|
|
13）Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007; 92: 546-9
|
|
|
|
|
|
14）Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33
|
|
|
|
|
|
15）Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008; 22: 1485-93
|
|
|
|
|
|
16）Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143: 777-84
|
|
|
|
|
|
17）Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009; 4: 745-54
|
|
|
|
|
|
18）Lee CK, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004; 33: 823-8
|
|
|
|
|
|
19）Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004; 73: 98-103
|
|
|
|
|
|
20）Dimopoulos MA, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory myeloma patients with impaired renal function. Cancer. 2010; 116: 3807-14
|
|
|
|
|
|
21）Dimopoulos MA, Christoulas D, Roussou M, et al. Lanalidomide and dexametahsone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010; 85: 1-5
|
|
|
|
|
|
22）Klein U, Neben K, Hielscher T, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011; 90: 429-39
|
|
|
|
|
|
23）Piro E, Molica S. A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? Acta Haematol. 2011; 126: 163-8
|
|
|
|
|
|
24）Kaygusuz I, Toptas T, Aydin F, et al. Bortezomib in patients with renal impairment. Hematology. 2011; 16: 200-8
|
|
|
|
|
|
25）Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011; 364: 2365-6
|
|
|
|
|
|
26）San Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008; 32: 842-9
|
|
|
|
|
|
27）Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005; 103: 1195-200
|
|
|
|
|
|
28）Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007; 109: 2604-6
|
|
|
|
|